Sanofi Shares Retreat After Halt of Phase 3 MOBILIZE Trial for Riliprubart
Sanofi shares declined after the company said it is discontinuing the Phase 3 MOBILIZE study of riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who did not respond to standard therapies. An independent data monitoring committee concluded the trial was unlikely to demonstrate sufficient efficacy. No safety conce…